Loading
JAK3 (Tyrosine-protein kinase JAK3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signalling events in both innate and adaptive immunity and plays a crucial role in haematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R.
CIViC holds 3 clinical evidence items and 0 assertions across 8 variants, naming Atezolizumab and Tofacitinib. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes clinical 0.96, affected pathway 0.61, literature 0.95, genetic association 0.18, somatic mutation 0.97, animal model 0.53). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Acute Lymphoblastic Leukaemia.
In plain words · JAK3 (Tyrosine-protein kinase JAK3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
JAK3 (Tyrosine-protein kinase JAK3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation.
No product in this corpus aims at JAK3 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA JAK3: RNA tissue enhanced (lymphoid tissue 53 nTPM); no normal tissue stained high. Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms, Leukaemia, Lymphoma, Skin cancer (all types), Lung cancer (all types), Colorectal cancer); Open Targets associates it with 3 specific cancer types at or above 0.5 (myelofibrosis, acquired polycythemia vera, essential thrombocythemia). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P52333; CIViC gene JAK3; IntOGen JAK3; Human Protein Atlas JAK3 tissue; Open Targets ENSG00000105639 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Kawamura et al, Proc. Natl. Acad. Sci. U.S.A, 1994, "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes". Source.
Sources: HGNC HGNC:6193 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P52333 (protein name, function text, keywords and locations (REST API)); CIViC gene JAK3 (3 evidence items, 0 assertions, 8 variants; diseases: Lung Adenocarcinoma, T-cell Acute Lymphoblastic Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000105639 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: colorectal cancer 0.52, acute lymphoblastic leukaemia 0.62, non-Hodgkin lymphoma 0.65, skin cancer 0.58, myeloproliferative neoplasm 0.73, acquired polycythemia vera 0.55 (GraphQL API, CC0)); IntOGen JAK3 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signalling events in both innate and adaptive immunity and plays a crucial role in haematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. Location: Endomembrane system; Cytoplasm (UniProt). Locus 19p13.11 (HGNC).
RNA: tissue enhanced (lymphoid tissue 53 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Lymph node, Spleen, Testis, Tonsil.
No cancer sample stained medium or high.
HPA JAK3 tissue · HPA JAK3 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"JAK3" OR ABSTRACT:"JAK3" OR TITLE:"Janus kinase 3" OR ABSTRACT:"Janus kinase 3" OR TITLE:"Tyrosine-protein kinase JAK3" OR ABSTRACT:"Tyrosine-protein kinase JAK3" OR TITLE:"L-JAK" OR ABSTRACT:"L-JAK" OR TITLE:"JAK3_HUMAN" OR ABSTRACT:"JAK3_HUMAN" OR TITLE:"JAK-3" OR ABSTRACT:"JAK-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JAK3, not a curated reading list.
Shares JAK-STAT signalling, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), IntOGen.